Medtronic Reports Second Quarter Fiscal 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Medtronic, Inc. (MDT) PT Lowered to $142 at Guggenheim
November 24, 2021 8:05 AM ESTGuggenheim analyst Chris Pasquale lowered the price target on Medtronic, Inc. (NYSE: MDT) to $142.00 (from $148.00) while maintaining a Buy rating.
The analyst commented, "MDT reported FY2Q22 revenue below Consensus estimates, though relatively in-line with weakened sentiment, in our view, while adj.... More
Medtronic, Inc. (MDT) PT Lowered to $140 at Stifel
November 23, 2021 5:49 PM ESTStifel analyst Rick Wise lowered the price target on Medtronic, Inc. (NYSE: MDT) to $140.00 (from $145.00) while maintaining a Buy rating following earnings.
The analyst commented, "We were hopeful that Medtronics F2Q22 (Oct.) would reflect more-visible US procedure volume recovery/improvements. This... More
Medtronic, Inc. (MDT) PT Lowered to $145 at Needham & Company
November 23, 2021 1:27 PM ESTNeedham & Company analyst Michael Matson lowered the price target on Medtronic, Inc. (NYSE: MDT) to $145.00 (from $152.00) while maintaining a Buy rating.
The analyst commented, "MDT's F2Q22 revenue missed consensus while EPS beat consensus and organic revenue growth slowed to 2.2% from 19.0% in... More
Medtronic (MDT) Tops Q2 EPS by 3c, Maintains FY EPS Guidance
November 23, 2021 6:46 AM ESTMedtronic (NYSE: MDT) reported Q2 EPS of $1.32, $0.03 better than the analyst estimate of $1.29. Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $7.96 billion.
GUIDANCE:
Medtronic sees FY2022 EPS of $5.65-$5.75, versus the consensus of $5.71.
The company today updated its revenue growth guidance and reiterated... More